MiamiHerald.comNovartis Heart Failure Drug Tops Standard in StudyBusinessweekNovartis AG (NOVN)'s experimental heart failure drug kept more patients in a study from dying or being hospitalized than the standard therapy, a result that could transform treatment of the disease that afflicts 26 million people worldwide. In a trial involving ...Novartis Study Shows New Heart Drug Cuts Cardiovascular DeathsWall Street JournalNew Heart Drug Saves More Lives Than Standard TreatmentTIMENew Novartis Drug Shows Striking Efficacy in Treating Heart FailureNew York TimesForbes -RTT News -Reuters UKall 16 news articles »